Compare CURR & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURR | REPL |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Singapore | United States |
| Employees | 293 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.8M | 407.1M |
| IPO Year | N/A | 2018 |
| Metric | CURR | REPL |
|---|---|---|
| Price | $2.99 | $9.98 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 152.3K | ★ 5.6M |
| Earning Date | 05-19-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $1.50 |
| 52 Week High | $4.73 | $13.24 |
| Indicator | CURR | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 45.31 | 69.45 |
| Support Level | $2.75 | $9.00 |
| Resistance Level | $3.71 | $10.71 |
| Average True Range (ATR) | 0.32 | 0.94 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 25.00 | 70.22 |
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.